How to buy GoodRx stock | $44.13

GoodRx is now publicly available to trade. The stock opened at $46, nearly 40% above it's IPO price of $33.

Launched in 2011, GoodRx allows customers to compare prescription drug prices. It's since become a household name, which may be one of the reasons that the stock has been getting so much buzz. If you're planning to invest, here's how you can buy in.

GoodRx stock price (NASDAQ: GDRX)

Use our graph to track the performance of GDRX stocks over time.

GoodRx shares at a glance

• Key figures

Information last updated 2021-09-25.

Latest market close	$44.13
52-week range	$26.66 - $64.22
50-day moving average	$38.89
200-day moving average	$36.67
Wall St. target price	$43.07
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.82

Buy GoodRx shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy GoodRx stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

GoodRx price performance over time

Historical closes compared with the close of $44.13 from 2021-09-24

1 week (2021-09-17)	-6.07%
1 month (2021-08-26)	24.70%
3 months (2021-06-25)	18.28%
6 months (2021-03-26)	16.04%

1 year (2020-09-25)	-15.20%
2 years (2019-09-22)	N/A
3 years (2018-09-22)	N/A
5 years (2016-09-22)	N/A

Is GoodRx under- or over-valued?

Valuing GoodRx stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of GoodRx's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

GoodRx's EBITDA

GoodRx's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $79.1 million.

The EBITDA is a measure of a GoodRx's overall financial performance and is widely used to measure a its profitability.

To put GoodRx's EBITDA into context you can compare it against that of similar companies.

• Teva Pharmaceutical Industries (TEVA.US): USD$4.4 billion
• Teladoc Health (TDOC.US): USD$18.8 million
• Humana (HUM.US): USD$4.2 billion

GoodRx financials

Revenue TTM	$631.1 million
Gross profit TTM	$521.1 million
Return on assets TTM	-21.43%
Return on equity TTM	-118.05%
Profit margin	-50.01%
Book value	$2.09
Market capitalisation	$17.5 billion

TTM: trailing 12 months

Shorting GoodRx shares

There are currently 15.9 million GoodRx shares held short by investors – that's known as GoodRx's "short interest". This figure is 2.3% down from 16.3 million last month.

There are a few different ways that this level of interest in shorting GoodRx shares can be evaluated.

GoodRx's "short interest ratio" (SIR)

GoodRx's "short interest ratio" (SIR) is the quantity of GoodRx shares currently shorted divided by the average quantity of GoodRx shares traded daily (recently around 1.8 million). GoodRx's SIR currently stands at 8.99. In other words for every 100,000 GoodRx shares traded daily on the market, roughly 8990 shares are currently held short.

To gain some more context, you can compare GoodRx's short interest ratio against those of similar companies.

• Teva Pharmaceutical Industries (TEVA.US): 3.52
• Teladoc Health (TDOC.US): 9.48
• Humana (HUM.US): 2.56

However GoodRx's short interest can also be evaluated against the total number of GoodRx shares, or, against the total number of tradable GoodRx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case GoodRx's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 GoodRx shares in existence, roughly 40 shares are currently held short) or 0.2564% of the tradable shares (for every 100,000 tradable GoodRx shares, roughly 256 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against GoodRx.

Find out more about how you can short GoodRx stock.

GoodRx share dividends

We're not expecting GoodRx to pay a dividend over the next 12 months.

You may also wish to consider:

• Humana (HUM.US) (0.66% forward annual dividend yield)

GoodRx overview

GoodRx Holdings, Inc. , through its subsidiaries, provides information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including telehealth services. The company serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. GoodRx Holdings, Inc. was incorporated in 2015 and is based in Santa Monica, California.

Frequently asked questions

What percentage of GoodRx is owned by insiders or institutions?
Currently 8.446% of GoodRx shares are held by insiders and 88.588% by institutions. How many people work for GoodRx?
Latest data suggests 450 work at GoodRx. When does the fiscal year end for GoodRx?
GoodRx's fiscal year ends in December. Where is GoodRx based?
GoodRx's address is: 2701 Olympic Boulevard, Santa Monica, CA, United States, 90404 What is GoodRx's ISIN number?
GoodRx's international securities identification number is: US38246G1085